
Medtronic (MDT) Stock Forecast & Price Target
Medtronic (MDT) Analyst Ratings
Bulls say
The positive outlook for Medtronic's stock is supported by notable growth in its neuromodulation segment, where the company gained 240 basis points of market share, alongside mid-single-digit revenue growth driven by the successful adoption of the MiniMed 780G AID system. Additionally, Medtronic's diabetes revenues reached $694 million, reflecting a robust 10.4% year-over-year organic growth that surpassed consensus expectations. The anticipated revenue increase of 3.4-3.8% for FY25, along with a 10-11% year-over-year growth in EPS, further positions Medtronic favorably in the market as it enhances its ecosystem within the lucrative electrophysiology ablation sector.
Bears say
The negative outlook on Medtronic's stock is primarily driven by projected revenue growth slowing to the low-single digits, attributed to unsuccessful new product launches and market share losses in certain categories. Additionally, the company faces ongoing risks such as disappointing sales from key new products, a flat or declining operating margin, and adverse currency impacts, which collectively contribute to concerns about below-consensus earnings. Furthermore, the company's recent decrease in R&D expenses coupled with an increase in SG&A expenditures indicates potential challenges in maintaining competitive positioning and profitability.
This aggregate rating is based on analysts' research of Medtronic and is not a guaranteed prediction by Public.com or investment advice.
Medtronic (MDT) Analyst Forecast & Price Prediction
Start investing in Medtronic (MDT)
Order type
Buy in
Order amount
Est. shares
0 shares